GSK affirms its long-term commitment to manufacturing in Scotland

The new £44 million facility at GSK Montrose will provide ingredients for over 400 million vaccinations a year. Significant investment in recent years re-affirms GSK’s belief that Scotland is an excellent base to manufacture and export to global markets. Built at a cost of £44M, the new facility at GSK’s site at Montrose in north-east Scotland will manufacture sterile aluminium salts which are compounds that...